COMPONENT is a randomised, double-blind, placebo-controlled, multi-centre, international Phase IIb study evaluating the efficacy of vidofludimus in RA with methotrexate, in comparison to methotrexate alone. A complete of 244 RA individuals were recruited because of this trial across 29 scientific trial sites in Poland, Romania, Bulgaria and the Czech Republic. ‘Completion of Element enrolment is a crucial milestone in the development of vidofludimus and ensures we are on the right track to see the Stage IIb final result in RA for this novel, oral inhibitor of IL-17 release,’ said Ulrich Dauer, CEO of 4SC AG. ‘Through the concentrated attempts of physicians and sufferers we have jointly been able to explore the efficacy of vidofludimus in a large population of RA individuals on MTX history and look forwards to presenting the data in 2011.’ The recently announced exploratory Phase IIa Entry trial of vidofludimus in inflammatory bowel disease met the primary endpoint and accomplished a response rate of 88 percent in Crohn’s disease and ulcerative colitis patients..Until October 2007 Follow-up continued. We identified potential research participants on the mature medical wards through a review of culture analyses of blood and cerebrospinal fluid from which S. Pneumoniae have been isolated. Patients who got survived a pneumococcal disease were invited to come back to the analysis clinic for screening 1 week after discharge. All patients were 15 years or old, resided within the Blantyre district, and were ready to go through an HIV test. All sufferers provided written educated consent. In order to avoid possible stigmatization of the study as an HIV trial, we offered enrollment to all or any patients in whom a pneumococcal infection had been diagnosed, of their HIV status regardless.